摘要
维甲酸(retinoic acid,RA)是维生素A的活性代谢产物,全反式维甲酸(all-trans-retinoic acid,ATRA)、13-顺式维甲酸(13-cis-retinoic acid,13-cRA)和9-顺式维甲酸(9-cis-retinoic acid,9-cRA)等是其同分异构体。维甲酸通过与其受体包括维甲酸受体和维甲酸X受体结合调控靶基因表达,在胚胎发育和细胞的生长及分化过程中发挥重要作用。全反式维甲酸治疗急性早幼粒白血病开创了分子靶向药物诱导肿瘤细胞分化治疗的先河,目前研究发现,维甲酸及其受体与肿瘤细胞的分化、增殖或凋亡等密切相关。就维甲酸及其受体与肿瘤关系的研究进展进行综述,为进一步研究奠定基础。
Retinoic acid is an active derivative of vitamin A. ATRA, 13-cRA and 9-cRA are the isomers ofretinoids. Combining with RARs and RXRs, RA plays important roles in embryonic development, cell growth and differentiation through regulating the target gene expression. ATRA has been successfully used in the differentiation therapy of APL （acute promyelocytic leukemia） in clinical. Current studies have found that the disturbance of RA and its receptors were also related to differentiation, proliferation or apoptosis of tumor cells. To develop novel mechanisms-based differentiation therapy, the relationship between RA or its receptors and tumors will be summarized in this review.
出处
《生命科学》
CSCD
2014年第3期295-301,共7页
Chinese Bulletin of Life Sciences
基金
大连市科技计划项目(2012E15-SF159)
国家自然科学基金项目(81072063)
关键词
维甲酸
受体
靶基因
调控
肿瘤
retinoic acid
receptors
target genes
regulation
tumors
